TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17360162

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Zuclopenthixol
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 15798297

Group type: EXPERIMENTAL
Intervention: Hand-held computerized soft tissue stiffness meter (STSM)
Number of subjects: 28
Study: 11773839

Group type: EXPERIMENTAL
Intervention: 10-minute daily treatments with eardrops for 2 weeks before surgery (Group A)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: 3-minute daily treatments for 2 weeks before surgery (Group B)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (Group C)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Preoperative positive bacteriology in surgical failures
Number of subjects: 101
Study: 9583576

Group type: EXPERIMENTAL
Intervention: Hypertonic saline (9%)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Isotonic saline (0.9%)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (0.9%) and Hypertonic saline (9%)
Number of subjects: 10
Study: 7649712

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS) injections (50 mg, one injection a week for five weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Glycosaminoglycan polysulfate (GAGPS) injections
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study: 2745867

Group type: EXPERIMENTAL
Intervention: Computer-aided pharmacokinetic method of aminoglycoside dose prediction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Nomogram approach based on creatinine clearance
Number of subjects: 100
Study: 1117912

Group type: EXPERIMENTAL
Intervention: Formula B (12 to 12 mg per liter iron, 32% linoleic acid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Formulas A and B (32% linoleic acid)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Formulas A and B
Number of subjects: 35

Group type: COMPARATOR
Intervention: Formulas C and D (lower amounts of unsaturated fatty acids)
Number of subjects: 35
Study: 29554961

Group type: EXPERIMENTAL
Intervention: Herbagut
Number of subjects: 50
Study: 27107097

Group type: EXPERIMENTAL
Intervention: Esomeprazole-based regimen (20 mg)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Omeprazole-based regimen (20 mg)
Number of subjects: 374
Study: 24884648

Group type: EXPERIMENTAL
Intervention: Instructions of an incompatible position task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moderate practice of the incompatible task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Instructions of a compatible spatial stimulus-response task
Number of subjects: 0
Study: 22959833

Group type: EXPERIMENTAL
Intervention: Early amniotomy (artificial rupture of membranes, ≤4 cm)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 20667858

Group type: EXPERIMENTAL
Intervention: Dyskinesia (group III)
Number of subjects: 259

Group type: COMPARATOR
Intervention: No dyskinesia (group I and II)
Number of subjects: 259
Study: 18478470

Group type: EXPERIMENTAL
Intervention: Procedure for prolapse and hemorrhoids (PPH)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Milligan-Morgan hemorrhoidectomy (MMH)
Number of subjects: 100
Study: 16096172

Group type: EXPERIMENTAL
Intervention: Femal (herbal remedy made from pollen extracts)
Number of subjects: 64
Study: 14633079

Group type: EXPERIMENTAL
Intervention: Terazosin (1 mg, twice-a-day) for 12 weeks
Number of subjects: 42
Study: 10963819

Group type: EXPERIMENTAL
Intervention: Once daily dosing of glibenclamide
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiple daily dosing of glibenclamide
Number of subjects: 30
Study: 8993084

Group type: EXPERIMENTAL
Intervention: Venlafaxine or bupropion
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Nonresponders (compared to healthy controls)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control group (healthy controls for nonresponders)
Number of subjects: 11
Study: 1456222

Group type: EXPERIMENTAL
Intervention: Superelastic arch wire
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multistranded steel arch wire
Number of subjects: 43

Group type: COMPARATOR
Intervention: Postextraction control phase
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Second arch wire (randomly allocated)
Number of subjects: 43
Study: 6703273

Group type: EXPERIMENTAL
Intervention: Epidural buprenorphine (60 micrograms in 10 ml of normal saline)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular morphine (0.15 mg/kg)
Number of subjects: 0
Study: 30088695

Group type: EXPERIMENTAL
Intervention: Cessation self-efficacy at baseline and at weeks 1, 3, 5, and 10 post-target quit date
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Concurrent smoking status verified using expired carbon monoxide
Number of subjects: 737

Group type: EXPERIMENTAL
Intervention: Week 10 abstinence
Number of subjects: 737
Study: 29400623

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Moderate Continuous Training (CONT)
Number of subjects: 11
Study: 26677830

Group type: EXPERIMENTAL
Intervention: Strength training alone (GS)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined strength and aerobic training in the same session (GCOM1)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Combined strength and aerobic training in 2 different sessions (GCOM2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (GC)
Number of subjects: 168
Study: 24714059

Group type: EXPERIMENTAL
Intervention: 12-month physical exercise intervention
Number of subjects: 371

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: 12-month physical exercise intervention in subgroup with poor/moderate WAI
Number of subjects: 371
Study: 23063221

Group type: EXPERIMENTAL
Intervention: Nonactivated single‐irrigation protocol (NAI) using 1% NaOCl
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Passive ultrasonic multi‐irrigation protocol (PUI) using 1% NaOCl, 17% EDTA, and 2% chlorhexidine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined NAI and PUI after CaOH(2) medication
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Second‐visit instrumentation
Number of subjects: 50
Study: 20067433

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Paroxetine (40 mg)
Number of subjects: 459
Study: 17340064

Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/d)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 16125367

Group type: EXPERIMENTAL
Intervention: TAR (Training Affect Recognition) - a computer-aided 12-session program focusing on facial affect recognition
Number of subjects: 77

Group type: COMPARATOR
Intervention: CRT (Cognitive Remediation Training) - aims to improve attention, memory, and executive functioning
Number of subjects: 77

Group type: COMPARATOR
Intervention: TAU (Treatment as Usual) - standard treatment without special training
Number of subjects: 77
Study: 11870530

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation: 46.2 Gy per 12 days, 1.4 Gy per fraction, three fractions per day with 6 h interfraction interval, treating 6 days per week
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional fractionation: 60 Gy per 6 weeks, 2 Gy per fraction, treating 5 days per week
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Accelerated hyperfractionation
Number of subjects: 70

Group type: COMPARATOR
Intervention: Conventional fractionation
Number of subjects: 70
Study: 10741095

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (NS)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (BDP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate plus salmeterol (BDP + S)
Number of subjects: 33
Study: 7857100

Group type: EXPERIMENTAL
Intervention: UFT with leucovorin tablet (400 mg/day of UFT with 20 mg/day of leucovorin)
Number of subjects: 34

Group type: COMPARATOR
Intervention: UFT alone (400 mg/day of UFT)
Number of subjects: 34
Study: 1678445

Group type: EXPERIMENTAL
Intervention: Ampicillin (25‐30 mg/kg body weight three times daily for 5 days) plus supportive care
Number of subjects: 889

Group type: COMPARATOR
Intervention: Supportive care only
Number of subjects: 889
Study: 6354606

Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31077610

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT) + Parent Psychoeducation (TEPSI)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 121
Study: 29423579

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided bilateral rectus sheath block (US-BRSB) with 30 ml of 0.25% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no sham block)
Number of subjects: 60
Study: 26875198

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate 400 mg tablets (test formulation)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Gleevec 400 mg tablets (control)
Number of subjects: 42
Study: 23731741

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 21710180

Group type: EXPERIMENTAL
Intervention: IUI 36 hours after hCG (Group I)
Number of subjects: 204

Group type: COMPARATOR
Intervention: IUI 24 hours after hCG (Group II)
Number of subjects: 204
Study: 19451553

Group type: EXPERIMENTAL
Intervention: Structured education group program (8-hour program delivered in 4 sessions over 4 weeks by a trained nurse educator)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Structured education group program
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 16815141

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate 500 mcg, twice daily for 2 weeks
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate
Number of subjects: 13
Study: 12766743

Group type: EXPERIMENTAL
Intervention: Rotational atherectomy
Number of subjects: 446

Group type: COMPARATOR
Intervention: Balloon angioplasty
Number of subjects: 446
Study: 10969673

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 9212476

Group type: EXPERIMENTAL
Intervention: Priming group (n = 20) received mivacurium 0.025 mg/kg followed by 0.225 mg/kg 3 min later
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non-priming group (n = 20) received mivacurium 0.25 mg/kg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study: 8402628

Group type: EXPERIMENTAL
Intervention: Vorozole racemate 1 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vorozole racemate 2.5 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vorozole racemate 5 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 3745460

Group type: EXPERIMENTAL
Intervention: Probability Scale employing Bayesian concepts and base rates
Number of subjects: 60
Study: 29554399

Group type: EXPERIMENTAL
Intervention: Merocel
Number of subjects: 100

Group type: COMPARATOR
Intervention: Glove finger
Number of subjects: 100
Study: 25869759

Group type: EXPERIMENTAL
Intervention: Hepatitis C with hepatic steatosis + NAFLD (Group 2)
Number of subjects: 405

Group type: COMPARATOR
Intervention: IBD + dyspepsia + hepatitis C without hepatic steatosis (Group 1)
Number of subjects: 405
Study: 24839862

Group type: EXPERIMENTAL
Intervention: Sucrose drink (100 g in 250 ml)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Glucose drink (50 g in 250 ml)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (artificial sweeteners in 250 ml)
Number of subjects: 43
Study: 22898118

Group type: EXPERIMENTAL
Intervention: CBT + Exercise (Exercise)
Number of subjects: 330

Group type: COMPARATOR
Intervention: CBT + Contact Control (Control)
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Exercise participation
Number of subjects: 330
Study: 19500864

Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in patients with reduced LVEF
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in patients with clinical signs of heart failure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Multi Slice Computed Tomography (MSCT) in relation to clinical signs of heart failure and reduced LVEF
Number of subjects: 40
Study: 18665934

Group type: EXPERIMENTAL
Intervention: Triple therapy plus yogurt (yogurt group, n = 168)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Triple therapy only (control group, n = 179)
Number of subjects: 347
Study: 17591649

Group type: EXPERIMENTAL
Intervention: Escalating energy protocol (protocol A: 100 J, 150 J, 200 J, 200 J)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Non-escalating energy protocol (protocol B: 200 J, 200 J, 200 J)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Non-escalating energy protocol (protocol B)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Escalating energy protocol (protocol A)
Number of subjects: 380
Study: 15219580

Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 11276273

Group type: EXPERIMENTAL
Intervention: Nabumetone (1,000 to 2,000 mg/d)
Number of subjects: 335

Group type: COMPARATOR
Intervention: Diclofenac (100 to 150 mg/d)
Number of subjects: 335
Study: 9137259

Group type: EXPERIMENTAL
Intervention: Polymyxin, tobramycin, and amphotericin (PTA)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Polymyxin, ciprofloxin, amphotericin (PCA)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Placebo (carrier only)
Number of subjects: 310
Study: 8193093

Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 3605397

Group type: EXPERIMENTAL
Intervention: 0.75 ml/kg of ethanol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.1 ml/kg of ethanol
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 1095282

Group type: EXPERIMENTAL
Intervention: Tolamolol, 16 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol, 8 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolamolol
Number of subjects: 16

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 16
Study: 31339100

Group type: EXPERIMENTAL
Intervention: PDSAFE (physiotherapy programme for fall prevention)
Number of subjects: 474
Study: 30425466

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control (no current given)
Number of subjects: 64
Study: 27129465

Group type: EXPERIMENTAL
Intervention: Crowdsourced HIV test promotion video
Number of subjects: 721

Group type: COMPARATOR
Intervention: Health marketing HIV test promotion video
Number of subjects: 721
Study: 24733445

Group type: EXPERIMENTAL
Intervention: Torsion adapter
Number of subjects: 10

Group type: COMPARATOR
Intervention: Rigid adapter
Number of subjects: 10
Study: 22850220

Group type: EXPERIMENTAL
Intervention: Pre-filled syringes
Number of subjects: 48

Group type: COMPARATOR
Intervention: Preparing infusions de novo from ampoules
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Infusions prepared by pharmacy and industry
Number of subjects: 48
Study: 19628371

Group type: EXPERIMENTAL
Intervention: Type A yogurt (mainly Lactobacillus plantarum SN35N)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Type B yogurt (mainly Lactobacillus plantarum SN13T)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Type C yogurt (mainly Lactococcus lactis A6 and Streptococcus thermophilus 510)
Number of subjects: 68
Study: 17089403

Group type: EXPERIMENTAL
Intervention: Tolcapone
Number of subjects: 150

Group type: COMPARATOR
Intervention: Entacapone
Number of subjects: 150
Study: 15589470

Group type: EXPERIMENTAL
Intervention: Tacrolimus and steroids
Number of subjects: 121

Group type: COMPARATOR
Intervention: Ciclosporin A, steroids, azathioprine, and ATG
Number of subjects: 121
Study: 12405554

Group type: EXPERIMENTAL
Intervention: High dose (HD) of 5 mg of LY 156735
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Low dose (LD) of 0.5 mg of LY 156735
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 8
Study: 10442206

Group type: EXPERIMENTAL
Intervention: Tramadol sustained release capsules with food intake
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tramadol sustained release capsules without food intake
Number of subjects: 24

Group type: COMPARATOR
Intervention: Instant release formulation
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sustained release tablet (reference substance)
Number of subjects: 24
Study: 8590851

Group type: EXPERIMENTAL
Intervention: Administration of rhG-CSF post chemotherapy with CHOP regimen
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Administration of rhG-CSF post chemotherapy with ProMACE/CytaBOM regimen
Number of subjects: 40

Group type: COMPARATOR
Intervention: Previous study without rhG-CSF administration
Number of subjects: 40
Study: 2609718

Group type: EXPERIMENTAL
Intervention: Carvedilol (5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine (2 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Nifedipine + Propranolol (2 mg + 5 mg)
Number of subjects: 10
Study: 991149

Group type: EXPERIMENTAL
Intervention: DTIC alone
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DTIC, CCNU, and vincristine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and vincristine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and hydroxyurea
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Combination of agents including DTIC
Number of subjects: 270

Group type: COMPARATOR
Intervention: Responders vs nonresponders
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DTIC, BCNU, and vincristine; DTIC, CCNU, and vincristine
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Patients without brain or liver metastasis
Number of subjects: 270

Group type: COMPARATOR
Intervention: Men vs women
Number of subjects: 270

Group type: COMPARATOR
Intervention: Site of primary lesion
Number of subjects: 270
Study: 31192538

Group type: EXPERIMENTAL
Intervention: Pola Office (pH = 2.0)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Pola Office Plus (pH = 7.0)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 28
Study: 25501356

Group type: EXPERIMENTAL
Intervention: Standard CWMT (45 min/session)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Shortened CWMT (15 min/session)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 38
Study: 25380538

Group type: EXPERIMENTAL
Intervention: Mobi-C cervical artificial disc (TDR)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 330
Study: 24536060

Group type: EXPERIMENTAL
Intervention: Figitumumab plus docetaxel/prednisone (Arm A)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Docetaxel/prednisone alone (Arm B1)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Crossover to Figitumumab plus docetaxel/prednisone (Arm B2)
Number of subjects: 204
Study: 23035175

Group type: EXPERIMENTAL
Intervention: ACE527 vaccine (10^11 CFU, two doses 21 days apart)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: ACE527 vaccine
Number of subjects: 70
Study: 19577029

Group type: EXPERIMENTAL
Intervention: Custom-made orthosis
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Commercial orthosis
Number of subjects: 23

Group type: COMPARATOR
Intervention: No orthosis
Number of subjects: 23
Study: 17244104

Group type: EXPERIMENTAL
Intervention: Ketamine (administered intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfentanil (administered intravenously)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Morphine (administered intravenously)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Other agents
Number of subjects: 0
Study: 15219645

Group type: EXPERIMENTAL
Intervention: Galanin (4 x 50 microg administered hourly)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Galanin
Number of subjects: 10
Study: 15203948

Group type: EXPERIMENTAL
Intervention: WalkSafe Program (intervention schools)
Number of subjects: 2300
Study: 11352392

Group type: EXPERIMENTAL
Intervention: DIAGNOdent
Number of subjects: 58

Group type: COMPARATOR
Intervention: Visual examination
Number of subjects: 58

Group type: COMPARATOR
Intervention: Radiographic examination
Number of subjects: 58
Study: 9142797

Group type: EXPERIMENTAL
Intervention: Admission LDH levels in patients with disseminated histoplasmosis
Number of subjects: 45

Group type: COMPARATOR
Intervention: Admission LDH levels in control group (patients with advanced AIDS)
Number of subjects: 45
Study: 8433725

Group type: EXPERIMENTAL
Intervention: Immediate percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 395

Group type: COMPARATOR
Intervention: Intravenous tissue plasminogen activator (t‐PA)
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Immediate PTCA
Number of subjects: 395

Group type: COMPARATOR
Intervention: Intravenous t‐PA
Number of subjects: 395
Study: 3315193

Group type: EXPERIMENTAL
Intervention: High-dose metoclopramide and lorazepam (M+L)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Prochlorperazine and lorazepam (P+L)
Number of subjects: 66
Study: 29516595

Group type: EXPERIMENTAL
Intervention: Heating pad applied on the patient's sacrum during the urodynamic study
Number of subjects: 74
Study: 28025924

Group type: EXPERIMENTAL
Intervention: Updated CMR recruitment script
Number of subjects: 105701

Group type: COMPARATOR
Intervention: Original CMR recruitment script
Number of subjects: 105701

Group type: EXPERIMENTAL
Intervention: Increased number of chronic medications
Number of subjects: 105701

Group type: EXPERIMENTAL
Intervention: Increased number of disease conditions
Number of subjects: 105701

Group type: EXPERIMENTAL
Intervention: Previous involvement in the MTMP
Number of subjects: 105701
Study: 26178724

Group type: EXPERIMENTAL
Intervention: Low-glycemic index dietary advice
Number of subjects: 566

Group type: COMPARATOR
Intervention: Healthy eating advice
Number of subjects: 566